AbbVie Expected To Ditch Abicipar After US FDA Setback

With a complete response letter for wet AMD drug abicipar, AbbVie is expected to move on from the drug acquired with Allergan. Molecular Partners now seems inclined to focus on IO, virology.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
FDA determined that abicipar's benefit don't outweigh its risk of intraocular inflammation

AbbVie Inc. seems unlikely to invest further resources or effort into anti-VEGF drug abicipar pegol for wet age-related macular degeneration (AMD) following a US Food and Drug Administration complete response letter on 26 June, and Molecular Partners AG, which discovered and initially developed the candidate, also appears to be positioning away from ophthalmology to increase its focus on cancer and virology programs.

Both companies announced the CRL on 26 June, noting that the FDA decided the drug has an unfavorable benefit-risk ratio...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

More from Scrip

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Can Bayer’s Pharmaceuticals Division Help It Weather A Perfect Storm?

 
• By 

Bayer continues to keep faith in its pharmaceuticals business despite a plethora of problems for the wider group with job cuts, continued debt concerns and ongoing glyphosate litigation claims.

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By 

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.